Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Last trade$0.4384
Day change-$0.1458 (-24.96%)
Day range$0.416 – $0.644
Volume804,437
Market cap$11M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$11.41M
Price / earnings
—
Price / book
-20.37×
Price / sales
8.35×
EV / sales
-0.77×
EV / EBITDA
0.12×
Profitability
Earnings per share
-$0.56
Return on assets
-49.12%
Return on equity
1,961.64%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.29×
Current ratio
0.99×
Quick ratio
0.99×
Cash ratio
0.75×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.76M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DARE, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$187.55K
$152.46K
$1.02M
$2.26K
-$21.17K
$25.43K
—
$41.69K
Cost of revenue
$319.89K
$242.33K
$295.8K
$0
$0
$0
$0
$0
Gross profit
-$132.34K
-$89.87K
$727.88K
$2.26K
-$21.17K
$25.43K
—
$41.69K
Selling, general and administrative
$2.59M
$2.25M
$1.58M
$2.5M
$2.38M
$2.31M
—
$2.04M
Research and development
$241.97K
$660.46K
$622.04K
$1.18M
$1.43M
$2.3M
—
$2.68M
Total operating expenses
$2.84M
$2.91M
$2.2M
$3.67M
$3.81M
$4.61M
—
$4.72M
Operating income
-$2.97M
-$3M
-$1.47M
-$3.67M
-$3.83M
-$4.58M
—
-$4.68M
Interest expense
$0
$0
$0
$0
$0
$0
—
$0
Income before taxes
-$2.98M
-$3M
-$1.44M
-$3.56M
-$4.02M
-$4.38M
—
-$4.7M
Income taxes
$0
$0
$0
$0
$0
$0
—
$0
Net income
-$2.98M
-$3M
-$1.44M
-$3.56M
-$4.02M
-$4.38M
—
-$4.7M
Net income attributable to common shareholders
-$2.98M
-$3M
-$1.44M
-$3.56M
-$4.02M
-$4.38M
—
-$4.7M
EBITDA
-$2.4M
-$2.44M
-$936.87K
-$3.19M
-$3.37M
-$4.41M
$6.37K
-$4.67M
Basic earnings per share
-$0.20
-$0.21
-$0.10
-$0.28
-$0.45
-$0.50
—
-$0.55
Diluted earnings per share
-$0.20
-$0.21
-$0.10
-$0.28
-$0.45
-$0.50
—
-$0.55
Recent news
Company coverage with links to the original publishers.
Dare Bioscience reported a Q3 loss of $0.18 per share, missing the consensus estimate of $0.13 loss by 38.46%. The company posted revenues of $0.05 million, missing estimates by 99.19%. DARE shares have declined 65.9% year-to-date versus the S&P 500's 10.5% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Daré Bioscience reported a Q2 2025 loss with negative revenue, but demonstrated progress in women's health product pipeline, including Sildenafil Cream and Ovaprene, while managing tight liquidity through strategic partnerships and grant funding.
Daré Bioscience announced a webinar on August 6, 2025, introducing DARE to PLAY™, a novel sildenafil cream designed to improve female sexual arousal, targeting prescription availability in Q4 2025.
Daré Bioscience announced positive findings from a Phase 2b study of its investigational topical cream Sildenafil Cream, 3.6% for the treatment of female sexual arousal disorder (FSAD). The study showed consistent results from patient-reported outcome measures, regardless of recall period, supporting the use of longer recall intervals which are less burdensome for patients.
Dare Bioscience, a biopharmaceutical company focused on women's health, has regained compliance with Nasdaq's minimum bid price requirement. The company's common stock achieved the necessary closing bid price of $1.00 or more per share over 10 consecutive trading sessions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.